Table 4 Bivariate analysis of variables collected during the ICU stay influencing the outcome, at ICU discharge, of pneumococcal CAP*
From: Severe pneumococcal pneumonia: impact of new quinolones on prognosis
Variables | Survivors n = 44 | Non survivors n = 26 | p |
|---|---|---|---|
Use of hydrocortisone | 12 (27.3%) | 12 (46.2%) | 0.1 |
Intensive insulin therapy | 18 (40.9%) | 12 (46.2%) | 0.66 |
Haemodialysis | 6 (13.6%) | 4 (15.4%) | 0.1 |
Improvement on D3 | 36 (81.8%) | 7 (26.9%) | <0.0001 |
SOFA >8 on D3 | 9 (20.5%) | 14 (53.8%) | <0.0001 |
SOFA >8 on D5 | 10 (22.7%) | 14 (53.8%) | 0.0001 |
SOFA >8 on D7 | 10 (22.7%) | 13 (50%) | 0.009 |
Sepsis-related complications | 14 (31.8%) | 17 (65.4%) | 0.006 |
HA-LRT superinfections | 8 (18.2%) | 9 (34.6%) | 0.12 |